- Kymera Therapeutics press release ( NASDAQ: KYMR ): Q3 GAAP EPS of -$0.79 misses by $0.05 .
- Revenue of $9.54M (-53.1% Y/Y) misses by $6.4M .
- Research and Development Expenses: Research and development expenses were $43.9 million for the third quarter of 2022 compared to $38.3 million for the third quarter of 2021.
-
Net Loss: Net loss was $43.0 million for the third quarter of 2022 compared to a net loss of $28.6 million for the third quarter of 2021.
-
Cash and Cash Equivalents: As of September 30, 2022, Kymera had approximately $595.6 million in cash, cash equivalents
For further details see:
Kymera Therapeutics GAAP EPS of -$0.79 misses by $0.05, revenue of $9.54M misses by $6.4M